VAKCINA

lalinea wrote:

Mór Thököly wrote:Reuters

The Balkan country expects to get 200,000 doses of the Sputnik V vaccine this month, 500,000 Sinopharm vaccines, around 90,000 doses developed by Pfizer Inc-BioNTech and "first quantities from over 100,000 shots" produced by AstraZeneca .

Odakle nama ovaj deal sa fajzerom?...

lalinea wrote:To je bukvalno jedna kutija nedeljno, jasno je to, ali super sto je i to neko imao foresight da ugovori. Jel se zna koliko su tacno doza ugovorili? Do kad ce nam slati tu kutiju nedeljno?

Vučić: Srbija će investirati koliko god bude potrebno da bi do kraja godine počela da proizvodi vakcinu Sputnjik V

Objavljeno: 5.02.2021

Srbija će investirati koliko god bude potrebno sredstava kako bi do kraja godine počela da proizvodi rusku vakcinu protiv koronavirusa "Sputnjik V", izjavio je danas predsednik Aleksandar Vučić agenciji Rojters.

On je rekao da je sa predsednikom Rusije Vladimirom Putinom postigao načelni dogovor o pokretanju proizvodnje koju je opisao kao "komplikovanu i tešku".

"U ovom trenutku nemamo (proizvodne) kapacitete (za Sputnjik V), ali ćemo ih izgraditi. Nije važno koliko će koštati, uložićemo", kazao je Vučić.

Naveo je da će cilj Srbije biti da proizvodi rusku vakcinu ne samo za sopstvene potrebe, već i za izvoz u zemlje regiona.

Tim ruskih stručnjaka, podseća Rojters, trebalo bi da poseti Srbiju sledeće nedelje radi razgovora o lokalnoj proizvodnji vakcine "Sputnjik V".

Rojters navodi da je Srbija jedna od prvih evropskih zemalja koja je počela masovnu vakcinaciju, sa milion kupljenih doza vakcine kineske državne kompanije Sinofarm.

Agencija ocenjuje da je zemlja na taj način "profitirala od bliskih veza s Kinom koja je investirala milijarde u Srbiju".

"Sa više od 530.000 ljudi vakcinisanih protiv korona virusa, što čini oko 7,5 odsto stanovništva, Srbija je na četvrtom mestu u svetu po stopi vakcinacije na 100 osoba, iza Izraela, Velike Britanije i SAD", navodi Rojters.

Američka agencija podseća da Srbija očekuje da tokom februara dobije 200.000 doza vakcine "Sputnjik V", 500.000 doza vakcina kineske firme Sinofarm, oko 90.000 doza vakcine kompanija Fajzer i Biontek , kao i prvu količinu od 100.000 doza vakcine kompanije Astrazeneka.

Vučić je rekao da će Srbija ove godine za nabavku dovoljne količine vakcina izdvojiti izmedju 200 i 300 miliona evra, odnosno do 0,7 odsto bruto domaćeg proizvoda, podseća Rojters.

Exclusive: Pfizer has withdrawn an application for emergency-use authorization of its COVID-19 vaccine in India that it has developed with Germany’s BioNTech, the company told @Reuters https://t.co/RIlUv7QypT via @krishnadas56

— Reuters (@Reuters) February 5, 2021

Expert panel had recommended against granting emergency use authorisation to #Pfizer COVID-19 vaccine just 2 days before the pharma major announced withdrawal of application for such approval in India: officials

— Press Trust of India (@PTI_News) February 5, 2021

NEW DELHI: The drug regulator's subject expert committee (SEC) has denied permission for emergency use authorization (EUA) to Pfizer's Covid-19 vaccine on grounds that causality of its reported adverse events are being probed and the company has not presented any plan to generate safety and immunogenicity data.
The committee – that met on Wednesday to consider the application from the US drugmaker - noted that “incidents of palsy, anaphylaxis and other SAE’s (serious adverse events) have been reported during post-marketing and the causality of the events with the vaccine is being investigated”.
“Further, the firm has not proposed any plan to generate safety and immunogenicity data in Indian population. After detailed deliberation, the committee has not recommended for grant of permission for emergency use in the country at this stage,” the SEC said in its recommendations.
From the beginning, the drug regulator has maintained that any foreign company with a vaccine candidate developed outside India will have to conduct at least bridging studies in India to ensure immunogenicity.
Pfizer was the first pharma company to apply for EUA for its Covid-19 vaccine – developed with Germany’s BioNTech - in the country.
The company later said that it has decided to withdraw its application at this time and may resubmit its approval request with additional information as it becomes available in the near future.
...

Dva primera, u bolnici od 700+ zaposlenih za prvi talas vakcinisanja se prijavilo 130 ljudi(toliko nas na spisku za revakcinu bilo)

U Mitrovici radi oko 900 prosvetara, za prvi talas se prijavilo toliko da su svi stali u kombi da se odvezu na vakcinašenje.

rumbeando wrote:desboj iz Sremske Mitrovice

UK and CureVac agree to work on vaccines against coronavirus variants

The British government ordered 50 million doses as part of the deal.

German biotech company CureVac is teaming up with the U.K. to develop its next generation of vaccines against new coronavirus variants, the British government said today.

As part of the deal, the U.K. has secured 50 million doses of the new vaccines "to be delivered later this year if they are required."

CureVac said that "any resulting vaccine candidates will be manufactured and distributed in the UK and its overseas and dependent territories" if approved by regulators.

“This fantastic new partnership means we can work to swiftly tweak and rollout new variations of existing vaccines if we need to, while also building up Britain’s vaccine manufacturing base in the process,” U.K. Business Secretary Kwasi Kwarteng said in a statement.

CureVac announced earlier this week that it was teaming up with pharmaceutical giant GSK to develop the new line of vaccines. The companies said they hope to have these new vaccines on the market by 2022.

CureVac's original mRNA-based coronavirus vaccine candidate is still undergoing large-scale human trials. The EU already has a contract with the firm for 225 doses of its shot, with the option to buy another 180 million.

Marius Lăcătuș wrote:aLI neMAmO peER ReVIeW!!!